Top Tech Companies (2,068)
Don't see your company?
Create a company profile
ManagedLab Services is a Certified Women Owned Small Business, leading the life science industry in Lab Support, Vendor Managed Inventory (VMI), and Project Management services for U.S. based labs of all sizes, from startup through large pharma. Our unique combination of highly trained PEOPLE, documented PROCESSes, and reportable DATA, tied to our vendor-agnostic approach, ensures your scientists always have what they need. We combine top-notch customer service with our deep expertise in best practices for Laboratory Operations and overlay that with cutting-edge automation to give you the most efficient lab available. A better alternative to...distributor managed inventory, temporary employees, and internal support staff. Visit our Website to learn more: www.managedlab.com
Altis has developed a patent-pending stem cell technology recreating the human intestinal epithelium for compound screening and microbiome research. The product is called RepliGut. It will allow drugs to be tested on an in vitro platform that more closely mimics native human biology. Our goal is to enable pharmaceutical companies to identify effective compounds earlier, before clinical trials; to reduce animal testing; and to make the drug development process faster, cheaper, and safer. Currently, 88% of drugs fail during clinical trials. Part of the reason is that during preclinical studies, drugs are tested using tumor cells and animals. These cannot accurately indicate the way that pharmaceuticals will behave in the human body. The current market lacks a viable method for testing drugs, prior to human testing, and RepliGut will more accurately reflect drug behavior in humans.
Targeting a better life for people with cancer is why we get up in the morning. It’s not enough to disrupt the progress of someone’s cancer; we want to keep cancer from disrupting someone’s life. That’s why everything we do is about developing the most precise, targeted cancer therapies. We believe this is the best way to get people back to their lives—back to living today, tomorrow, and beyond. Because for us, targeting a better now is the only thing that matters. ImmunoGen is a leader in developing antibody-drug conjugates (ADCs). Our lead product candidate, mirvetuximab soravtansine, is a first-in-class folate receptor alpha (FRα)-targeting ADC with multiple studies underway in ovarian cancer. Our second pivotal program, IMGN632, is a CD123-targeting ADC being studied as a monotherapy in BPDCN and in combination in AML. Our earlier-stage assets in development are IMGC936, an ADAM9-targeting ADC in co-development with MacroGenics, and IMGN151, our next generation anti-folate receptor alpha ADC. Learn more about who we are, what we do, and how we do it at www.immunogen.com.
Revolo Biotherapeutics is developing revolutionary therapies powered to reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases. Its two drug candidates, ‘1805 and ‘1104, a protein and a peptide respectively, reset the immune system by preventing the chronic pro-inflammatory immune response that results in autoimmune or allergic disease. ‘1805 is a modified analogue of a key molecule in immune function and is in clinical development for moderate-to-severe rheumatoid arthritis and non-infectious uveitis. ‘1104 is a peptide derived from a natural immune-regulatory protein and is in clinical development for patients with eosinophilic esophagitis (EoE) and allergic disease. The disease-agnostic mechanism of action of Revolo Biotherapeutic’s assets provides a potential platform for the development of treatments for multiple autoimmune and allergic diseases. Visit www.revolobio.com to learn more.
Spirovant Sciences is developing novel gene therapies for cystic fibrosis and other pulmonary diseases. We are the only company advancing programs with both AAV and lentivirus vectors.
Scientist.com is the world’s largest marketplace for medical research. We help pharmaceutical scientists discover life-saving medicines in less time and at lower cost. Our mission is to make it possible to cure all human disease by 2050. By connecting scientists and enabling them to exchange ideas and transact seamlessly online, Scientist.com is speeding up and reducing the cost of medical research. We were founded in 2007, launched our first research outsourcing marketplace in 2008 and built our first enterprise marketplace for Pfizer in 2009. Today, we operate enterprise marketplaces for 20 of the world’s top 30 pharmaceutical companies, 80 biotechnology companies and the US National Institutes of Health (NIH).
Rx Return Services is a premier Pharmaceutical Reverse Distribution Company. Our goal is to provide the best Pharmaceutical Return Service possible in the most efficient, simple and cost-effective way. We take great pride in getting our customers the maximum amount of money for their expired returnable drugs, while at the same time providing safe destruction of the unusable pharmaceutical products.
Orna Therapeutics is a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA) therapeutics with the potential to change the way we treat disease. Orna’s proprietary platform combines novel technology to create oRNAs that drive protein expression with validated and unique delivery solutions.
Life Biosciences is dedicated to developing novel therapies to extend healthy human lifespan by targeting the biological causes of aging. Founded in 2017 and headquartered in Boston, MA, we are pursuing therapies targeting three molecular pathways that regulate the biology of aging: mitochondrial uncoupling, chaperone-mediated autophagy, and epigenetic reprogramming. Our platform approach enables us to develop medicines with the potential to prevent, treat, and/or reverse multiple aging-related diseases, each with critical unmet needs.
ZAGENO is on a mission to accelerate scientific innovation by streamlining biotech purchasing processes with its award-winning, first-of-its-kind e-commerce platform. With over 25 million product SKUs available from more than 5,000 unique product brands, ZAGENO makes online shopping for any research material convenient, efficient and reliable. The ZAGENO experience includes its Scientific Score, a best-in-class product rating system that offers unbiased, peer-reviewed ratings to support accurate purchasing decisions. Available on desktop, tablet, and mobile devices, ZAGENO makes biotech purchases easier than ever and is an ideal sales channel for suppliers and partners. Founded in 2015, the company is headquartered in the United States and has additional offices in Germany, and Poland. For more information, visit www.zageno.com.
Gritstone bio brings together a group of distinguished scientific founders and advisors, a highly experienced and diverse leadership team and a seasoned and successful board of directors to tackle fundamental challenges at the intersection of cancer genomics, immunotherapy and other precision therapy areas, specifically in COVID-19 and HIV. With our unique approach to immuno-oncology and infectious diseases, we seek to generate a therapeutic immune response by leveraging insights into the immune system’s ability to recognize and destroy diseased cells by targeting select antigens. We started with a focus on tumor-specific neoantigens and more recently extended our programs to include viral antigens displayed on the surface of virus-infected cells. The biology underlying immune system recognition of targets on the surface of abnormal cells is common to both anti-tumor and anti-viral immunity. Consequently, we believe that activating and directing the immune system to these targets could offer an important opportunity to extend the benefits of immunotherapy for more patients.
Life Edit is a next-generation gene editing company dedicated to paving the way to faster, safer, more innovative gene editing therapeutics that treat diseases once thought to be incurable. Our platform allows us to target any genomic sequence and develop life-changing therapies for the most challenging genetic disorders. Life Edit has one of the world’s largest and most diverse arrays of novel RNA-guided nucleases and base editors that are active in mammalian cells. They were developed from a proprietary collection of non-pathogenic organisms, and offer gene editing tools with higher fidelity, novel functionality, reduced immune response risk, and easier delivery. Our genome editing platform is derived from AgBiome’s proprietary collection of tens of thousands of microbes. We retain access to this growing microbial collection to mine for gene editing systems with uses in human therapeutics. Life Edit is an Elevatebio portfolio company. We are focused on strengthening our platform, developing a pipeline of gene therapies, and sharing our expertise through strategic partnerships.
Headquartered in Brooklyn, New York, Cresilon, Inc. is a privately-held medical device company focused on hemostatic technologies that improve wound care and advance the standard of medical treatments. For more information, visit Cresilon.com. We are always looking for dynamic people to join our team as we dive into a range of challenges at the forefront of science and technology—to learn more about our openings please visit https://cresilon.workable.com/.
Elephas is developing a technology platform to assess how live tumor cells respond to cancer therapies. We are harnessing the latest advances in cancer biology, multimodal microscopy, engineering, and artificial intelligence to revolutionize cancer treatment. Cancer is a leading cause of death worldwide, with the number of patients projected to triple by 2060. Despite advances in precision medicine and a significant increase in the number of available therapies, many cancer patients still derive no benefit from their treatment. Immunotherapy is an emerging type of treatment that can greatly benefit patients when it is successful. Unfortunately, today only 1 in 3 patients receiving therapy respond and only 1 in 5 receiving immunotherapy respond. We maintain the native 3-dimensional cellular architecture of a patient’s tumor and enable ex-vivo real-time profiling of live tumor samples. The platform is being developed for use with immunotherapy agents alone and in combination with traditional chemotherapy and targeted therapies. THE ELEPHAS MISSION To develop innovative cancer diagnostic products and services that enable accurate prediction of clinical treatment outcomes and accelerate drug development
HelixNano is building the world's most advanced mRNA platform to enable previously impossible applications across human and non-human biology
Vow is a cultured meat company, founded and operated in Sydney, Australia. We’re a multidisciplinary team of scientists, technologists and designers, all working together to make sustainable food both irresistible and available to billions of people.
Our mission is to develop groundbreaking therapies to reverse mitochondrial dysfunction by leveraging a deep mechanistic understanding of mitochondrial biology. Mitochondria are essential energy-converting cellular organelles found in nearly every cell type throughout the body. Dysfunctional mitochondria are involved in more than 50 diseases. The most severe of these are broadly termed mitochondrial diseases, a group of rare genetic conditions which affect individuals of all ages. Mitochondrial dysfunction also plays an important role in more common diseases, including aging-related disorders. At Pretzel, we are developing first-in-class therapeutics that can address mitochondrial dysfunction at its roots. By taking aim at the genetic drivers of mitochondrial dysfunction, we believe our approach could be effective across a wide range of diseases which lack meaningful treatment options today.
AOA Dx is developing the next frontier in early-stage cancer detection through its pioneering work in glycolipids and proprietary biomarker technology. Our revolutionary tumor marker ganglioside platform, GlycoLocate™, is paving the way for life-saving early cancer detection. In a first of its kind, AOA Dx has developed AKRIVIS GD™, an early-stage liquid biopsy test for ovarian cancer, that has proven excellent sensitivity and specificity in a recent study. We foresee novel tumor biomarker gangliosides as the future for diagnosis, prognosis, monitoring, and eventually targeted therapies across multiple cancers. AOA Dx was co-founded by three experts and passionate advocates of women’s health, who have worked together at two previous diagnostic startups, that both resulted in successful exits upon commercialization. AOA Dx, a Y combinator and VC backed company, raised an oversubscribed Seed Round to accelerate development and clinical studies. Awards & Accelerators: 1. Y Combinator 2. MassChallenge 3. Springboard Enterprises 4. MassMedic Ignite 5. Inc Magazine Top 100 Female Founders 6. Women's Health Innovation Summit Award 7. Massachusetts Life Sciences Center MassNextGen Award 8. The Wave Summit's Emerging Women Founder in Bio Award 9. The Eddies Award www.aoadx.com
Carmine Therapeutics, headquartered in Cambridge MA, is pioneering a new class of non-viral gene therapies based on red blood cell extracellular vesicles, combined with proprietary payloads. In June 2020, Carmine inked a research alliance with Takeda Pharmaceuticals worth up to $900 million to develop non-viral gene therapies for 2 targets. Carmine has also been named one of the FierceBiotech’s Fierce 15 Biotech companies of 2020 and was also awarded the Bristol-Myers Squibb "Golden Ticket". Carmine was founded in 2019 by EVX Ventures, Professors Harvey Lodish (Whitehead, MIT), Minh Le and Jiahai Shi. Professor Lodish, who was a founding member of several successful biotech companies that include Genzyme and Millennium Pharmaceuticals, is also Chair of the Scientific Advisory Board of Carmine. For more information, visit www.carminetherapeutics.com Media Relations [email protected] Investor Relations [email protected]
Mantra Bio is harnessing exosomes to deliver safe, highly targeted medicines. We are the creator of REVEAL™, an exosome engineering platform combining computational biology and lab automation to generate targeted exosome vehicles (TEVs) for a broad set of therapeutic areas.
